• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
76,913.50 -582.86
( -0.75%)
Global Indices
Nasdaq
48,888.32 -274.62
(-0.56%)
Dow Jones
7,157.73 -2.07
(-0.03%)
Hang Seng
59,153.23 -764.23
(-1.28%)
Nikkei 225
10,371.76 158.65
(1.55%)
Forex
USD-INR
94.52 0.35
(0.37%)
EUR-INR
110.65 0.18
(0.17%)
GBP-INR
127.71 0.18
(0.14%)
JPY-INR
0.59 0.00
(0.25%)

EQUITY - MARKET SCREENER

HDFC Asset Management Company Ltd
Industry :  Finance & Investments
BSE Code
ISIN Demat
Book Value()
541729
INE127D01025
215.444739
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
HDFCAMC
41.79
119476.24
EPS(TTM)
Face Value()
Div & Yield %
66.73
5
1.94
 

Lupin receives USFDA approval for Dapagliflozin and Metformin Hydrochloride XR Tablets
Apr 08,2026
Lupin today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg. The company also received tentative approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 2.5 mg/1,000 mg.

The U.S. FDA has approved Lupin's Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets as bioequivalent to Xigduo® XR for the indications in the approved labeling.